Last reviewed · How we verify
NCT04719273
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Phase 2 trial testing Extended-release Onapristone in Refractory Endometrial Adenocarcinoma in 14 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Thomas Jefferson University |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 28 January 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Extended-release Onapristone
- Anastrozole (anastrozole) — full drug profile →
- Quality-of-Life Assessment
- Questionnaire Administration
- Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)
- Progesterone Receptor Positive ( PGR Positive; PR Positive)
Conditions studied
- Refractory Endometrial Adenocarcinoma — all drugs for Refractory Endometrial Adenocarcinoma →
- Refractory Endometrial Carcinoma — all drugs for Refractory Endometrial Carcinoma →
- Refractory Endometrial Clear Cell Adenocarcinoma — all drugs for Refractory Endometrial Clear Cell Adenocarcinoma →
- Refractory Endometrial Endometrioid Adenocarcinoma — all drugs for Refractory Endometrial Endometrioid Adenocarcinoma →
Sponsor
Thomas Jefferson University
Who can join
18 and older, female only, with Refractory Endometrial Adenocarcinoma or Refractory Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the tumor cells. Anastrozole is a drug that blocks the production of estrogen in the body. Giving onapristone with anastrozole may work better than anastrozole alone in treating patients with hormone receptor positive endometrial cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04719273
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Thomas Jefferson University trials
Trials by the same sponsor.
- NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
- NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
- NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04719273 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
- Last refreshed: 8 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04719273.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing